Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Cardiol Therapeutics (CRDL)

December 2, 2025 6:43 AM EST Send to a Friend
H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $9.00 price target on Cardiol Therapeutics (NASDAQ: CRDL).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login